OCA
ALLO icon

OpenArc Corporate Advisory’s Allogene Therapeutics ALLO Stock Holding History

OpenArc Corporate Advisory’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362K Buy
174,258
+2,000
+1% +$4.39K ﹤0.01% 570
2026
Q1 		$420K Buy
172,258
+9,274
+6% +$18.6K 0.01% 494
2025
Q4 		$223K Buy
+162,984
New +$215K ﹤0.01% 588

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

OpenArc Corporate Advisory's ALLO Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Allogene Therapeutics (ALLO) stake by 1.2% in Q2 2026, buying an estimated $4.39K and bringing the position to 174,258 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #570.

OpenArc Corporate Advisory first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $420K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • OpenArc Corporate Advisory held 174,258 shares of Allogene Therapeutics worth $362K as of Q2 2026.
  • OpenArc Corporate Advisory bought 2,000 Allogene Therapeutics shares in Q2 2026, an estimated $4.39K.
  • Allogene Therapeutics made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #570 holding.
  • OpenArc Corporate Advisory first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • OpenArc Corporate Advisory's Allogene Therapeutics position peaked at $420K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.